Business
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACE
About this update from Alumis Inc.
[{"type":"image","alt":"Alumis Inc.","displaySize":"","headline":null,"caption":"Alumis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1V_aGoKejvy_01T3BfhbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911","width":150,"height":39}},"lazy":false},{"type":"text","content":"– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 –","length":259,"tagName":"p"},{"type":"text","content":"– Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 –","length":202,"tagName":"p"},{"type":"text","content":"– Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 –","length":177,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the year ended December 31, 2024, and highlighted recent achievements and upcoming milestones.","length":428,"tagName":"p"},{"type":"text","content":"“Alumis concluded a strong 2024, continuing to establish our late-stage pipeline of next-generation oral TYK2 inhibitors that have the potential to address significant unmet patient needs in immune-mediated diseases around the world,” said Martin Babler, President and Chief Executive Officer of Alumis. “The next 12-18 months will bring major milestones for Alumis, with topline data from the pivotal Phase 3 program for ESK-001 in moderate-to-severe plaque psoriasis expected in the first quarter of 2026. We also plan to initiate a Phase 2 trial of A-005 in multipl...